For physician Vishal Khetpal, the legal battle between Hims & Hers and Novo Nordisk (which, by the way, was settled yesterday) is just one symptom of something much larger going on with American ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

As the Super Bowl approached halftime, Hims & Hers publicly staked its claim to preventive medicine in front of the American people. In a one-minute ad, the direct-to-consumer health company ...

AI scribe company Nabla aims to be much more by using tech from Yann LeCun's new startup AMI, which just raised $1 billion.

The co-founders of the Covid-19 vaccine developer BioNTech plan to leave the biotech to start a new mRNA-focused company ...

Removing race from the eGFR had a big impact, resulting in 5.3 more kidney transplants per 1000 Black candidates.

Ugur Sahin and Özlem Türeci, the couple who co-founded BioNTech, are leaving the Covid-19 vaccine maker to start a new, mRNA-focused firm.

The number of potential antimicrobial treatments being developed by the world’s largest drugmakers nosedived by 35% over the past five years, according to a new analysis.

Novo Nordisk and Hims & Hers have reached a deal that, for now, appears to end their bitter dispute around Hims’ sale of compounded versions of Novo’s blockbuster obesity drug Wegovy.

Vertex said a drug it secured as part of a $4.9 billion acquisition successfully reduced by half a key marker of a kidney disease known as IgA nephropathy.

A battle between doctors and a hospital system is an early test of a new law designed to separate business and medicine.

The FDA is cutting back on public advisory committee meetings, even as the public and other stakeholders seek more transparency.